Eli Lilly CEO on how Covid antibody drug helped drive Q4 earnings

Eli Lilly’s fourth-quarter profit jumped 41.5%, helped by higher demand for its diabetes drugs and a successful launch of its Covid-19 antibody treatment. David Ricks, chairman and chief executive officer of Eli Lilly, joined "Squawk Box" on Friday to discuss the results.